You are here

Article info

Article menu

Download PDFPDF

Abstracts
Prime time session: treatment targets and novel therapies
22 New and approved therapies for SLE: Anifrolumab

Authors

Citation

Vollenhoven RV
22 New and approved therapies for SLE: Anifrolumab
Lupus Science & Medicine 2022;9:doi: 10.1136/lupus-2022-la.22

Publication history

  • First published April 6, 2022.
Online issue publication 
April 06, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .